10 High Growth Healthcare Stocks to Invest in Now

6. Genmab A/S (NASDAQ:GMAB)

Revenue Growth: 40.37% 

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company specializing in innovative antibody therapeutics for cancer and other serious diseases. The company’s core business focuses on developing differentiated antibody-based medicines, leveraging proprietary platforms like DuoBody, HexaBody, and DuoHexaBody to create highly targeted therapies with enhanced efficacy and safety profiles.

According to the analysts, Genmab A/S (NASDAQ:GMAB) has established itself as a major participant in the market thanks to its antibody therapies, with drugs like Darzalex seeing commercial success. Furthermore, Epkinly’s (epcoritamab) recent introduction should be a game-changer. Interestingly, this can serve as the cornerstone of treatment for diffuse large B-cell lymphoma (DLBCL). This gives the company an advantage over rivals in the lymphoma market.

Genmab A/S (NASDAQ:GMAB) reported over DKK 15 billion in revenue for the first nine months of 2024 which shows a 29% year-over-year increase. This growth was driven by a 37% rise in recurring revenue, which now constitutes 92% of total revenue, up from 86% the previous year. Profitability has also shown significant improvement, with operating profit increasing by 27% to over DKK 4.5 billion.

Genmab A/S (NASDAQ:GMAB)’s potential as a high-growth healthcare stock is supported by its expanding portfolio, with eight approved products developed in-house or leveraging its technologies. The company boasts a strong pipeline with ongoing Phase 3 trials for EPKINLY, Rina-S, and acasunlimab, and strategic partnerships with major pharmaceutical firms like AbbVie and Johnson & Johnson enhance its market presence.

As of Q3 2023, 14 hedge fund holders held shares in the company, as tracked by the Insider Monkey database. The largest stakeholder in the company was Renaissance Technologies with shares worth $43,553,115. Street analysts hold a consensus Moderate Buy rating on the stock with an average 12-month price target of $39.00, with estimates ranging from $27.00 to $50.00, representing an 88.86% potential upside from the current price of $20.65.